prikaz prve stranice dokumenta Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound
  Preuzmi
PDF 227.81 KB
Ostalo - Sažetak s konferencije
Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound
European Journal of Nuclear Medicine and Molecular Imaging, 47 (2020), suppl. 1; S194-S195. https://doi.org/10.1007/s00259-020-04988-4
Punda, M.; Petranović-Ovčariček, P.; Gladić-Nenadić, V.; Šiško-Markoš, I.; Franceschi, M.; Jukić, T.

Citiranost:
,
Citirajte ovaj rad

Punda, M., Petranović Ovčariček, P., Gladić Nenadić, V., Šiško Markoš, I., Franceschi, M. i Jukić, T. (2020). Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound. European Journal of Nuclear Medicine and Molecular Imaging, 47. (suppl. 1), S194-S195. doi: 10.1007/s00259-020-04988-4

Punda, M., et al. "Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound." European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, br. suppl. 1, 2020, str. S194-S195. https://doi.org/10.1007/s00259-020-04988-4

Punda, M., P. Petranović Ovčariček, V. Gladić Nenadić, I. Šiško Markoš, M. Franceschi i T. Jukić. "Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound." European Journal of Nuclear Medicine and Molecular Imaging 47, br. suppl. 1 (2020): S194-S195. https://doi.org/10.1007/s00259-020-04988-4

Punda, M., et al. (2020) 'Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound', European Journal of Nuclear Medicine and Molecular Imaging, 47(suppl. 1), str. S194-S195. doi: 10.1007/s00259-020-04988-4

Punda M, Petranović Ovčariček P, Gladić Nenadić V, Šiško Markoš I, Franceschi M, Jukić T. Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound. European Journal of Nuclear Medicine and Molecular Imaging [Internet]. 2020. [pristupljeno 01.04.2025.];47(suppl. 1):S194-S195. doi: 10.1007/s00259-020-04988-4

M. Punda, P. Petranović Ovčariček, V. Gladić Nenadić, I. Šiško Markoš, M. Franceschi i T. Jukić, "Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound", European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, br. suppl. 1, str. S194-S195, 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:262212. [Citirano: 01.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:262212
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound
AutorM. Punda
AutorP. Petranović-Ovčariček
AutorV. Gladić-Nenadić
AutorI. Šiško-Markoš
AutorM. Franceschi
AutorT. Jukić
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Breast cancer (BC) patients receiving advanced specific anti-neoplastic treatments are at increased risk for cancer treatment-induced bone loss. The guidelines recommend bone mineral density (BMD) testing by dual-energy X-ray absorptiometry (DXA) and exclusion of secondary causes for low BMD such as primary hyperparathyroidism (PHPT).
Jezikengleski
Vrsta publikacijeOstalo - Sažetak s konferencije
Status objaveObjavljen
Vrsta recenzijeNepoznato
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEuropean Journal of Nuclear Medicine and Molecular Imaging
Brojčani podacivol. 47, br. suppl. 1, str. S194-S195
p-ISSN1619-7070
e-ISSN1619-7089
DOIhttps://doi.org/10.1007/s00259-020-04988-4
URN:NBNurn:nbn:hr:220:262212
Datum objave publikacije2020
SkupNaziv: Annual Congress of the European Association of Nuclear Medicine
Kratica: EANM‘20
Lokacija: Virtual, Njemačka
Organizator: European Association of Nuclear Medicine
Datum početka: 2020-10-22
Datum završetka: 2020-10-30
URL dokumentahttps://link.springer.com/article/10.1007/s00259-020-04988-4
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2025-03-19 09:33:31
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.